Premium
Alpha‐1‐adrenergic blockade and lipoprotein metabolism in essential hypertension
Author(s) -
Ferrier Claudia,
BerettaPiccoli Carlo,
Weidmann Peter,
Mordasini Rubino
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.218
Subject(s) - terazosin , blood pressure , endocrinology , plasma renin activity , essential hypertension , medicine , aldosterone , lipoprotein , diuretic , chemistry , blood lipids , pharmacology , cholesterol , renin–angiotensin system , hyperplasia
The effect of the selective α 1 ‐antagonist terazosin on serum lipoproteins and certain blood pressure–regulating factors was assessed in 15 patients with essential hypertension. Terazosin given during 8 weeks reduced arterial pressure (from 153/103 ± 3/2 (SE) to 143/96 ± 5/2 mm Hg; P < 0.02) but did not modify body weight, heart rate, blood volume, plasma renin activity, aldosterone and catecholamine levels, or serum cholesterol, triglycerides, and their lipoprotein fractions. In nine of the patients, blood pressure control was not achieved with terazosin monotherapy and the diuretic methyclothiazide, 2.5 mg, was added. After 8 weeks of combined treatment, blood pressure decreased further (P < 0.05); serum lipids and lipoprotein fractions did not change as compared with placebo or terazosin conditions. These findings indicate that terazosin in monotherapy does not unfavorably influence lipid metabolism. Clinical Pharmacology and Therapeutics (1986) 40, 525–530; doi: 10.1038/clpt.1986.218